Stryker SYK
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Stryker (SYK) Business Model and Operations Summary
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one fourth of Stryker's total revenue currently comes from outside the United States.
Key Insights
Stryker (SYK) Core Market Data and Business Metrics
Latest Closing Price
$373.3Market Cap
$142.54 BillionPrice-Earnings Ratio
40.01Total Outstanding Shares
381.69 Million SharesTotal Employees
53,000Dividend
$0.84 Per Share QuarterlyIPO Date
February 1, 1988SIC Description
Surgical & Medical Instruments & ApparatusPrimary Exchange
New York Stock ExchangeHeadquarters
1941 Stryker Way, Portage, MI, 49002
Historical Stock Splits
If you bought 1 share of SYK before May 17, 2004, you'd have 2 shares today.
| Execution Date | Split Amount |
|---|---|
| May 17, 2004 | 2-for-1 |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow | $1.99 Billion |
| Net Cash Flow From Operating Activities | $3.84 Billion |
| Net Cash Flow From Financing Activities, Continuing | $983 Million |
| Net Cash Flow From Investing Activities, Continuing | $-2.85 Billion |
| Net Cash Flow, Continuing | $1.97 Billion |
| Net Cash Flow From Financing Activities | $983 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Diluted Earnings Per Share | $9.33 |
| Basic Average Shares | $381 Million |
| Preferred Stock Dividends And Other Adjustments | $0 |
| Income Tax Expense/Benefit | $600 Million |
| Revenues | $21.97 Billion |
| Research and Development | $1.46 Billion |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss Attributable To Parent | $3.46 Billion |
| Other Comprehensive Income/Loss | $-129 Million |
| Comprehensive Income/Loss | $3.46 Billion |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Other Current Assets | $8.42 Billion |
| Prepaid Expenses | $961 Million |
| Liabilities And Equity | $43.83 Billion |
| Equity Attributable To Parent | $20.15 Billion |
| Assets | $43.83 Billion |
| Current Assets | $14.67 Billion |
Historical Dividends
Current dividend: $0.84 Per Share Quarterly
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| Feb 5, 2025 | Apr 30, 2025 | Mar 31, 2025 | $0.84 | Quarterly |
| Dec 10, 2024 | Jan 31, 2025 | Dec 31, 2024 | $0.84 | Quarterly |
| Aug 7, 2024 | Oct 31, 2024 | Sep 30, 2024 | $0.8 | Quarterly |
| May 9, 2024 | Jul 31, 2024 | Jun 28, 2024 | $0.8 | Quarterly |
| Feb 7, 2024 | Apr 30, 2024 | Mar 29, 2024 | $0.8 | Quarterly |
| Dec 5, 2023 | Jan 31, 2024 | Dec 29, 2023 | $0.8 | Quarterly |